Approval · Notice of Compliance 30012 · 2023
TEVA-TICAGRELOR: Notice of Compliance 30012
Issued January 31, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30012
- Date
- January 31, 2023
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Update to Labels. Update to the Package Insert. Response to Advisement Letter
- Canadian reference product
- BRILINTA (Astrazeneca Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-TICAGRELOR | Not yet assigned | — |
Medicinal ingredients
- TICAGRELOR 60 MG per TAB
- TICAGRELOR 90 MG per TAB